Unidade de Investigación en Cardioloxía Celular e Molecular
C.C.M.
![Foto de Unidade de Investigación en Cardioloxía Celular e Molecular](/img/grupo.png)
![Foto de Stanford University](/img/noimage_org.png)
Stanford University
Stanford, Estados UnidosPublicacións en colaboración con investigadores/as de Stanford University (4)
2019
-
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628
-
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
The Lancet, Vol. 394, Núm. 10204, pp. 1169-1180
2018
-
Alirocumab and cardiovascular outcomes after acute coronary syndrome
New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107
2015
-
Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF
Journal of the American Heart Association, Vol. 5, Núm. 3